01:54 PM EDT, 04/04/2024 (MT Newswires) -- eFFECTOR Therapeutics ( EFTR ) Chief Executive Officer Steve Worland said there is no "obvious path forward to continue developing tomivosertib in frontline NSCLC" based on the data currently available after disclosing topline results for the phase 2 trial of tomivosertib combined with pembrolizumab in non-small cell lung cancer.

The stock plummeted 81% as intraday volume topped 7.79 million shares versus the daily average of 163,000.

AXT (AXTI) shares slumped 25% after short seller JCapital Research said the material science company "may be on the brink of collapse" and "US investors know little of the peril."

Volume topped 3.93 million versus the daily average of 2.32 million.

Lamb Weston ( LW ) reported fiscal Q3 adjusted earnings and sales below market expectations and lowered its guidance for fiscal 2024.

Shares dropped 18% with volume topping 16.5 million versus the daily average of 1.52 million.

Price: 3.15, Change: -13.32, Percent Change: -80.87